Compassionate Use of Sodium Stibogluconate (Pentostam) for Cutaneous and Mucocutaneous New World Leishmaniasis

Expanded access is currently available for this treatment.

Verified by University of California, San Francisco, July 2007

Sponsored by:	University of California, San Francisco
Information provided by:	University of California, San Francisco
ClinicalTrials.gov Identifier:	NCT00508963

Purpose

Patients with biopsy proven new world cutaneous or mucocutaneous leishmaniasis will be treated with sodium stibogluconate (Pentostam).

Condition	Intervention
Leishmaniasis, Cutaneous Leishmaniasis, Mucocutaneous	Drug: sodium stibogluconate (Pentostam)

MedlinePlus related topics: Leishmaniasis

Drug Information available for: Sodium stibogluconate

Study Type:	Expanded Access
Official Title:	Compassionate Use of Sodium Stibogluconate (Pentostam) for Cutaneous and Mucocutaneous New World Leishmaniasis

Further study details as provided by University of California, San Francisco:

Intervention Details:

20 mg/kg IV every day for 20 or 28 days

Eligibility

Ages Eligible for Study:	18 Years and older
Genders Eligible for Study:	Both

Criteria

Inclusion Criteria:

Exclusion Criteria:

Contacts and Locations

Please refer to this study by its ClinicalTrials.gov identifier: NCT00508963

Contacts

Contact: Jane E Koehler, MA, MD

415-476-3536

Locations

United States, California
University of CA at San Francisco Hospitals and Clinics
San Francisco, California, United States, 94143

Sponsors and Collaborators

University of California, San Francisco

Investigators

Principal Investigator:	Timothy Berger, MD	University of CA at San Francisco
Principal Investigator:	Lindy Fox, MD	University of CA at San Francisco

More Information

Study ID Numbers:	UCSF Infectious Diseases
Study First Received:	July 27, 2007
Last Updated:	April 15, 2008
ClinicalTrials.gov Identifier:	NCT00508963
Health Authority:	United States: Food and Drug Administration

Keywords provided by University of California, San Francisco:

New World Cutaneous or Mucocutaneous Leishmaniasis

Study placed in the following topic categories:

Leishmaniasis, Mucocutaneous
Leishmaniasis
Protozoan Infections
Skin Diseases, Infectious

Antimony Sodium Gluconate
Skin Diseases
Parasitic Diseases
Leishmaniasis, Cutaneous

Additional relevant MeSH terms:

Anti-Infective Agents
Antiprotozoal Agents
Antiparasitic Agents
Skin Diseases, Parasitic
Antiplatyhelmintic Agents
Therapeutic Uses

Anthelmintics
Sarcomastigophora Infections
Mastigophora Infections
Schistosomicides
Pharmacologic Actions

ClinicalTrials.gov processed this record on January 16, 2009